메뉴 건너뛰기




Volumn 9, Issue 1, 2014, Pages 1-7

Efficacy and safety of sofosbuvir in the treatment of chronic hepatitis C: The dawn of a new era

Author keywords

Hcv; Interferon; Interferon free combination; Polymerase inhibitors; Randomized clinical trial; Sofosbuvir

Indexed keywords

INTERFERON; PEGINTERFERON; PLACEBO; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT;

EID: 84898449283     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/1574887108666131213120354     Document Type: Review
Times cited : (24)

References (53)
  • 1
    • 78751621217 scopus 로고    scopus 로고
    • Evolving epidemiology of hepatitis C virus
    • Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-15.
    • (2011) Clin Microbiol Infect , vol.17 , pp. 107-115
    • Lavanchy, D.1
  • 8
    • 0030928695 scopus 로고    scopus 로고
    • Hepatitis C: The clinical spectrum of disease
    • Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997; 26: 15S-20S.
    • (1997) Hepatology , vol.26
    • Hoofnagle, J.H.1
  • 9
    • 10744225097 scopus 로고    scopus 로고
    • Global burden of disease (GBD) for hepatitis C
    • Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20-9.
    • (2004) J Clin Pharmacol , vol.44 , pp. 20-29
  • 12
    • 35648970573 scopus 로고    scopus 로고
    • Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin
    • Braks RE, Ganne-Carrie N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, Pol S, Trinchet JC. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007; 13: 5648-53.
    • (2007) World J Gastroenterol , vol.13 , pp. 5648-5653
    • Braks, R.E.1    Ganne-Carrie, N.2    Fontaine, H.3    Paries, J.4    Grando-Lemaire, V.5    Beaugrand, M.6    Pol, S.7    Trinchet, J.C.8
  • 13
    • 4644224871 scopus 로고    scopus 로고
    • Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy
    • Tsuda N, Yuki N, Mochizuki K, Nagaoka T, Yamashiro M, Omura M, Hikiji K, Kato M. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol 2004; 74: 406-13.
    • (2004) J Med Virol , vol.74 , pp. 406-413
    • Tsuda, N.1    Yuki, N.2    Mochizuki, K.3    Nagaoka, T.4    Yamashiro, M.5    Omura, M.6    Hikiji, K.7    Kato, M.8
  • 14
    • 77951648047 scopus 로고    scopus 로고
    • Surrogate endpoints and non-inferiority trials in chronic viral hepatitis
    • Gentile I, Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol 2010; 52: 778.
    • (2010) J Hepatol , vol.52 , pp. 778
    • Gentile, I.1    Borgia, G.2
  • 16
    • 65449136656 scopus 로고    scopus 로고
    • Diagnosis, management, and treatment of hepatitis C: An update
    • Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
    • (2009) Hepatology , vol.49 , pp. 1335-1374
    • Ghany, M.G.1    Strader, D.B.2    Thomas, D.L.3    Seeff, L.B.4
  • 21
    • 84871109075 scopus 로고    scopus 로고
    • Efficacy of Pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: A meta-analysis
    • Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of Pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infect Dis 2012; 12: 1471-2334.
    • (2012) BMC Infect Dis , vol.12 , pp. 1471-2334
    • Coppola, N.1    Pisaturo, M.2    Tonziello, G.3    Sagnelli, C.4    Sagnelli, E.5    Angelillo, I.F.6
  • 25
    • 84896126011 scopus 로고    scopus 로고
    • Prediction of sustained virologic responses to combination therapy of pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C infection
    • Ismail MH. Prediction of sustained virologic responses to combination therapy of pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C infection. J Family Community Med 2013; 20: 35-40.
    • (2013) J Family Community Med , vol.20 , pp. 35-40
    • Ismail, M.H.1
  • 29
    • 0035990966 scopus 로고    scopus 로고
    • Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection
    • Distante S, Bjoro K, Hellum KB, Myrvang B, Berg JP, Skaug K, Raknerud N, Bell H. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002; 22: 269-75.
    • (2002) Liver , vol.22 , pp. 269-275
    • Distante, S.1    Bjoro, K.2    Hellum, K.B.3    Myrvang, B.4    Berg, J.P.5    Skaug, K.6    Raknerud, N.7    Bell, H.8
  • 31
    • 79960824576 scopus 로고    scopus 로고
    • Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: A meta-analysis
    • Deltenre P, Louvet A, Lemoine M, Mourad A, Fartoux L, Moreno C, Henrion J, Mathurin P, Serfaty L. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol 2011; 55: 1187-94.
    • (2011) J Hepatol , vol.55 , pp. 1187-1194
    • Deltenre, P.1    Louvet, A.2    Lemoine, M.3    Mourad, A.4    Fartoux, L.5    Moreno, C.6    Henrion, J.7    Mathurin, P.8    Serfaty, L.9
  • 34
    • 84873029732 scopus 로고    scopus 로고
    • Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients
    • Katz LH, Goldvaser H, Gafter-Gvili A, Tur-Kaspa R. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients. Cochrane Database Syst Rev 2012; 12.
    • (2012) Cochrane Database Syst Rev , pp. 12
    • Katz, L.H.1    Goldvaser, H.2    Gafter-Gvili, A.3    Tur-Kaspa, R.4
  • 35
    • 79961234860 scopus 로고    scopus 로고
    • Treatment extension benefits HCV genotype 1 patients without rapid virological response: A systematic review
    • Gevers TJ, Slavenburg S, van Oijen MG, Drenth JP. Treatment extension benefits HCV genotype 1 patients without rapid virological response: a systematic review. Neth J Med 2011; 69: 216-21.
    • (2011) Neth J Med , vol.69 , pp. 216-221
    • Gevers, T.J.1    Slavenburg, S.2    van Oijen, M.G.3    Drenth, J.P.4
  • 37
    • 84857532001 scopus 로고    scopus 로고
    • Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients
    • Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients. World J Gastroenterol 2012; 18: 800-5.
    • (2012) World J Gastroenterol , vol.18 , pp. 800-805
    • Nimer, A.1    Mouch, A.2
  • 38
    • 83755196636 scopus 로고    scopus 로고
    • Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients
    • Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 2011; 17: 5184-90.
    • (2011) World J Gastroenterol , vol.17 , pp. 5184-5190
    • Abu-Mouch, S.1    Fireman, Z.2    Jarchovsky, J.3    Zeina, A.R.4    Assy, N.5
  • 39
    • 84896959418 scopus 로고    scopus 로고
    • Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection
    • in press. PMID: 24081499, DOI: 10.1007/s10096-013-1985-7
    • Coppola N, Marrone A, Pisaturo M, Starace M, Signoriello G, Gentile I, Adinolfi LE, Sagnelli E, Zampino R. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis 2013 in press. PMID: 24081499, DOI: 10.1007/s10096-013-1985-7.
    • (2013) Eur J Clin Microbiol Infect Dis
    • Coppola, N.1    Marrone, A.2    Pisaturo, M.3    Starace, M.4    Signoriello, G.5    Gentile, I.6    Adinolfi, L.E.7    Sagnelli, E.8    Zampino, R.9
  • 40
    • 80053339008 scopus 로고    scopus 로고
    • An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
    • Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
    • (2011) Hepatology , vol.54 , pp. 1433-1444
    • Ghany, M.G.1    Nelson, D.R.2    Strader, D.B.3    Thomas, D.L.4    Seeff, L.B.5
  • 45
    • 84883404339 scopus 로고    scopus 로고
    • A novel promising therapeutic option against hepatitis C virus: An oral nucleotide NS5B polymerase inhibitor sofosbuvir
    • Gentile I, Borgia F, Buonomo AR, Castaldo G, Borgia G. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem 2013; 20: 3733-42.
    • (2013) Curr Med Chem , vol.20 , pp. 3733-3742
    • Gentile, I.1    Borgia, F.2    Buonomo, A.R.3    Castaldo, G.4    Borgia, G.5
  • 47
    • 84993833509 scopus 로고    scopus 로고
    • Minimal impact of sofosbuvir plus ribavirin on health related quality of life (HRQL) compared to pegylated inter feron plus ribavirin for chronic hepatitis C (CH-C): Results from FISSION plus positron studies
    • Younossi ZM, Stepanova M, Mir HM, Jacobson IM, Gane E, Nader F, Hunt S. Minimal impact of sofosbuvir plus ribavirin on health related quality of life (HRQL) compared to pegylated inter feron plus ribavirin for chronic hepatitis C (CH-C): results from FISSION plus positron studies. J Hepatol 2013; 58: S577-S.
    • (2013) J Hepatol , vol.58
    • Younossi, Z.M.1    Stepanova, M.2    Mir, H.M.3    Jacobson, I.M.4    Gane, E.5    Nader, F.6    Hunt, S.7
  • 49
    • 84881403455 scopus 로고    scopus 로고
    • Sofosbuvir for previously untreated chronic hepatitis C infection
    • Hsu CS. Sofosbuvir for previously untreated chronic hepatitis C infection: N Engl J Med 2013 Aug 15; 369(7): 678.
    • (2013) N Engl J Med , vol.369 , Issue.7 , pp. 678
    • Hsu, C.S.1
  • 52
    • 84862664371 scopus 로고    scopus 로고
    • EASL clinical practice guidelines: Management of chronic hepatitis B virus infection
    • EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
    • (2012) J Hepatol , vol.57 , pp. 167-185
  • 53
    • 33749447547 scopus 로고    scopus 로고
    • Treating chronic hepatitis B: Today and tomorrow
    • Borgia G, Gentile I. Treating chronic hepatitis B: today and tomorrow. Curr Med Chem 2006; 13: 2839-55.
    • (2006) Curr Med Chem , vol.13 , pp. 2839-2855
    • Borgia, G.1    Gentile, I.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.